BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+1.50 (+1.24%)
As of 3:05PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close121.43
Bid122.34 x 900
Ask122.68 x 800
Day's Range121.49 - 124.31
52 Week Range87.49 - 199.70
Avg. Volume519,090
Market Cap6.776B
Beta (3Y Monthly)3.05
PE Ratio (TTM)N/A
EPS (TTM)-11.35
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est178.17
Trade prices are not sourced from all markets
  • Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
    Motley Fool5 days ago

    Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

    These drugs and the biotechs that make them could be on the way to tremendous success in the near future.

  • Benzinga9 days ago

    Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade

    Bluebird bio Inc (NASDAQ: BLUE ) held its Analyst Day in New York last week, and at least one analyst came away less bullish on the stock. The Analyst Wedbush's David Nierengarten downgraded bluebird bio ...

  • Barrons.com9 days ago

    Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.

    At least one analyst left (BLUE)’s (ticker: BLUE) analyst day last week concerned about the development-stage biotech firm’s pricing plans for its new gene therapy treatment. Bluebird Bio shares were down 2.7% when the market opened on Wednesday morning, following a report by Wedbush’s David Nierengarten, who downgraded his rating of the firm to Neutral from Outperform, with a 12-month price target of $166, to neutral, with a 12-month price target of $131. Bluebird Bio, which went public in 2013, develops high-priced cell and gene therapies that target rare illnesses.

  • Business Wire15 days ago

    bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies

    bluebird bio, Inc. (BLUE) today will host an Analyst Day in New York that will highlight significant progress in the company’s emerging immuno-oncology and severe genetic disease pipeline, provide updates on launch expectations for its first gene therapy product and share key aspects of its long-term growth strategy. The company also is announcing a new research collaboration with Seattle Children’s Research Institute in Acute Myeloid Leukemia (AML), a Phase 1/2 study planned in Merkel Cell Carcinoma (MCC) with the Fred Hutchinson Cancer Research Center and programs in Diffuse Large B-cell Lymphoma (DLBCL) and MAGE-A4 positive solid tumors.

  • bluebird bio Flies Forward
    Motley Fool16 days ago

    bluebird bio Flies Forward

    An approval for Zynteglo is imminent.

  • Markit17 days ago

    See what the IHS Markit Score report has to say about bluebird bio Inc.

    bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * Bearish sentiment is high * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BLUE had net inflows of $1.87 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y
    Zacks18 days ago

    bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y

    bluebird (BLUE) reports wider-than-expected Q1 loss. Nevertheless, the pipeline progress looks encouraging.

  • Business Wire21 days ago

    bluebird bio Announces Investor Events in May

    To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at Replays of the webcasts will be available on the bluebird bio website for 90 days following the events. bluebird bio is pioneering gene therapy with purpose.

  • Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
    Zacks22 days ago

    Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of -6.79% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press22 days ago

    Bluebird: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of $2.99 per share. The results fell short of Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research ...

  • Business Wire22 days ago

    bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress

    – Received positive opinion from CHMP for ZYNTEGLO™ gene therapy for patients 12 years and older with transfusion-dependent β-

  • Business Wire23 days ago

    Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine

    Celgene Corporation (CELG) and bluebird bio, Inc. (BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies’ lead investigational BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy candidate for patients with relapsed and refractory multiple myeloma. The manuscript, “Anti-BCMA CAR T Cell Therapy bb2121 in Relapsed/Refractory Multiple Myeloma”, published in NEJM includes key safety and efficacy results from the dose escalation and first expansion cohort, including a minimum of six months follow up on all subjects. Patients in the study were heavily pre-treated, with a median of seven prior multiple myeloma treatment regimens (range, 3 to 23), which included prior treatment with immunomodulatory drugs, proteasome inhibitors and daratumumab in the majority of patients.

  • Business Wire23 days ago

    bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer

    bluebird bio, Inc. (BLUE), has appointed Joanne Smith-Farrell, Ph.D., to chief business officer. In this role, Joanne will lead corporate development and strategy, and she will also continue to serve as our oncology franchise leader. “Under Joanne’s leadership, bluebird has built a strong corporate development team that has executed on significant deal flow, enhancing our emerging immuno-oncology and severe genetic disease pipeline and expanding our set of tools, technologies, capabilities and partners,” said Jeff Walsh, chief strategy officer, bluebird bio.

  • 5 Biotech Stocks for a Long-Lived Portfolio
    InvestorPlace24 days ago

    5 Biotech Stocks for a Long-Lived Portfolio

    While the biotech sector saw early gains in 2019, the selling pressure has picked up steam recently as the government continued its scrutiny over the Medicare system and the pricing model for drugs. Not only are biotechnology stocks lower, but so are drug stores and drug plan suppliers. But this could be creating an interesting entry poinnt. Investors could invest in all of those sectors but the biotechnology stocks could prove the most rewarding.Biotechnology companies spend enormous amounts of money and time developing drugs. They will eventually prove to the government that rising product prices are a necessity in developing novel and better drugs. Should they succeed and a drug comes to market, everyone wins. * 7 Stocks to Buy That Ought to Buy Back Shares Patients who need the drug will have another treatment option. Drug plan providers may negotiate better prices and offerInvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech Stocks to Buy: Regeneron Pharmaceuticals (REGN)Source: Shutterstock Regeneron Pharmaceuticals (NASDAQ:REGN) fell 14% on news that its competitor, Novartis AG (NYSE:NVS), secured a speedy review for brolucizumab for use in wet, age-related macular degeneration. In August 2018, the FDA approved Regeneron's marketing for Eylea. But if Novartis has a superior product, this could put pressure on one of Regeneron's major product lines.In 2018, Eylea sales topped $4.1 billion, up from $3.7 billion in 2017.Markets chose to ignore the ongoing success of Regeneron's Dupixent drug. In 2018, sales topped $922 million. The high efficacy and safety profile of the injectable drug will surely drive sales higher this year and beyond. Dermira (NASDAQ:DERM) may have announced good Phase 2b study results last month but the company is a long way away from releasing a competitive product. Sarepta Therapeutics (SRPT)Source: Shutterstock Sarepta Therapeutics (NASDAQ:SRPT) lost about one-third of its value from 52-week highs. Markets are still unhappy over the company's $350 million share offering announced in March. The company said that it would use the proceeds "for the continuation and initiation of further clinical trials, commercialization, manufacturing, business development activities, including the potential licensing or acquisition of complementary products, technologies and entities."More recently, Sarepta presented a positive development in its gene therapy. With four patients involved in the age group of 4-7, the study met the primary end-point for safety. Secondary endpoints included a decrease in CK and a change in micro-dystrophin expression before and after treatment.In the fourth quarter, Sarepta reported revenue increasing 47.3% Y/Y to $84.4 million. Still, even though the company reported a loss of $2.05 a share (GAAP), EXONDYS 51 revenue for the year topped $301.1 million. The company's NDA filing for golodirsen with priority review and a PDUFA of August 19 is notable. Golodirsen advances Sarepta's RNA strategy. The drug is for patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53.If the company receives approval, it would gain another 8% of the Duchenne community. * 7 A-Rated Stocks That Are Under $10 In the fourth quarter, Sarepta tripled its R&D spending, to $146.2 million. $10.4 million of the costs in clinical and manufacturing expenses also include a ramp up in manufacturing activities for Golodirsen.Sarepta is scheduled to report first-quarter results on May 29, after market close. Incyte Corporation (INCY)Source: Eastern Washington University via Flickr (modified)Incyte Corporation's (NASDAQ:INCY) 14% monthly drop on the stock market, to a recent closing price of $73.52, should pique value investor interest. In the fourth quarter, the company reported revenue growing 25.2% to $468.4 million. Non-GAAP EPS came in at 40 cents.The markets may have a memory that is too short-term. In the quarter, it saw a growth of 22% from Jakafi, 19% from Iclusig and 28% growth in Jakavi royalties. Jakafi is used for the treatment of intermediate or high-risk myelofibrosis. Management forecast Jakafi sales of $1.58 billion to $1.65 billion in 2019. Olumiant is now adding meaningfully to the company's top-line results. The drug is used to treat adults with moderate to severely active rheumatoid arthritis.Incyte forecasts the royalty revenue for both Jakavi and Olumiant growing by around 20%. Overall, sales are expected to grow by between 14% and 19% in 2019.Management is confident that its rich product portfolio will accelerate revenue growth. Already, top-line growth is due to revenue growth exceeding expense growth.Incyte's strong balance sheet, with cash growing to $1.4 billion last year, gives the company the flexibility to develop products. Pursuing Phase 1 products will take a few years to pay off. Investors who are patient and buy and hold INCY stock will get rewarded if these projects are successful. Vertex Pharmaceuticals (VRTX)Source: Shutterstock Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a narrow range of between $180-$190 for most of 2019, only to fall below $168 in recent sessions. Investors may be getting nervous over its valuation, where its forward P/E is 28 times.Vertex grows through investing in transformative medicines that offer a benefit, regardless of modality. It develops drugs for cystic fibrosis while expanding its pipeline. In 2018, it initiated clinical development of CRISPR-Cas9 treatment in Beta -Thalassemia and Sickle cell disease. This year, it aims to advance one or more compounds from research into clinical development.Vertex reported revenue from the CF product line topping $3.04 billion in 2018, up from $2.17 billion in 2017. The company saw a sharp increase in the number of patients being treated by its approved medicines. The launch of Symdeko in the U.S. and multiple label expansions for Kalydeco and Orkambi also added meaningfully to results.In 2019 and beyond, the company forecasts that with a triple combination regimen, it has the potential to increase treatment from ~44,000 to ~68,000 worldwide.Non-GAAP operating income also grew sharply, from $564 million in 2017 to $1.11 billion in 2018. For 2019, Vertex forecasts operating income of $1.35 billion. * 7 Cloud Stocks to Buy Now The 15 analysts who cover VRTX stock have, according to Tipranks, $209 price target, which implies the stock could rise by 23% in the next year. Investors should look at Vertex after the stock's recent drop. Bluebird bio (BLUE)Source: Shutterstock Bluebird bio (NASDAQ:BLUE) fell about 12% in the last week alone, on no company-specific news. Just as markets quickly forgot the strong quarterly earnings report for the other biotech stocks mentioned, investors did the same with BLUE stock.Bluebird expects LentiGlobin in TDT, a gene therapy, to win approval in 2019. But the company said the launch will be country-by-country progressive in Europe. The upside of this approach is that the company will not commit any major hiccups on the launch. The downside is that the revenue growth from sales will be slow. However, this should not concern investors who have a long-term time horizon in mind.Last December 2018, the company presented new data for LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT). It also discussed results for its Phase 1/2 HGB-206 study. And in November 2018, it completed enrollment for its Phase 2 study evaluating the efficacy and safety of bb2121 in patients with relapsed/refractory multiple myeloma.Bluebird ended the fourth quarter with $1.9 billion in cash equivalents and marketable securities. With the most recent cash raise of $600.6 million in July 2018, the company is unlikely to issue any more shares in the short-term. Instead, the company may invest prudently in its clinical studies to advance drug development. Any good news from these studies will drive the stock price back to yearly highs.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 3 Scorching Hot Bank Stocks to Consider Now * 10 Stocks to Sell Before They Give Back 2019 Gains * 7 Stocks to Buy That Ought to Buy Back Shares Compare Brokers The post 5 Biotech Stocks for a Long-Lived Portfolio appeared first on InvestorPlace.

  • Zacks24 days ago

    Small Gains Still Bring New Highs

    Small Gains Still Bring New Highs

  • 20 High-Growth Stocks For The Next 20 Years
    Motley Fool25 days ago

    20 High-Growth Stocks For The Next 20 Years

    If you're hunting for top growth stocks to add to long-term portfolios, you ought to consider these fast-growing companies.

  • Is a Beat in the Cards for Molina's (MOH) Earnings in Q1?
    Zacks26 days ago

    Is a Beat in the Cards for Molina's (MOH) Earnings in Q1?

    Molina Healthcare's (MOH) Q1 earnings will gain from membership growth and its streamlining efforts. However, the same might be partially offset by contract losses and the company's Marketplace business.

  • How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
    Motley Fool27 days ago

    How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life

    A new payment proposal that directly affects hospitals could also boost sales of some expensive new cancer therapies.

  • Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates
    Zacks28 days ago

    Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates

    Universal Health's (UHS) first-quarter earnings are affected by a pre-tax unrealized loss.

  • What's in Store for HCA Healthcare's (HCA) Q1 Earnings?
    Zacks28 days ago

    What's in Store for HCA Healthcare's (HCA) Q1 Earnings?

    HCA Healthcare (HCA) is likely to gain from higher admissions. However, escalating expenses might weigh down its margins.

  • Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings?
    Zacks28 days ago

    Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings?

    WellCare Health's (WCG) first-quarter earnings are likely to gain from a rise in membership, partly offset by high debt load.

  • Why bluebird bio, Inc.'s (NASDAQ:BLUE) CEO Pay Matters To You
    Simply Wall St.29 days ago

    Why bluebird bio, Inc.'s (NASDAQ:BLUE) CEO Pay Matters To You

    Nick Leschly has been the CEO of bluebird bio, Inc. (NASDAQ:BLUE) since 2010. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth that the business...

  • Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?
    Zacks29 days ago

    Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?

    Tenet Healthcare (THC) is likely to be hit by declining revenues in the first quarter of 2019.

  • Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y
    Zackslast month

    Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y

    Anthem's (ANTM) Q1 earnings surge on the back of a solid operating performance and strong growth across all core businesses.